Galzin (Zinc Acetate) Patent Expiration, LOE Window & CMS Spending

Galzin (Zinc Acetate) by Eton: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $294K 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEton
FDA Application & PathwayN020458 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$294K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$294K
Reported Wholesale Price Change (CA SB 17)10 WAC filings (max 1555.1% 2-yr change)